These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 35618549)

  • 1. Management of drug-drug interactions with nirmatrelvir/ritonavir in patients treated for Covid-19: Guidelines from the French Society of Pharmacology and Therapeutics (SFPT).
    Lemaitre F; Grégoire M; Monchaud C; Bouchet S; Saint-Salvi B; Polard E; ; ; ; ; ;
    Therapie; 2022; 77(5):509-521. PubMed ID: 35618549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nirmatrelvir Plus Ritonavir: First Approval.
    Lamb YN
    Drugs; 2022 Apr; 82(5):585-591. PubMed ID: 35305258
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
    Hashemian SMR; Sheida A; Taghizadieh M; Memar MY; Hamblin MR; Bannazadeh Baghi H; Sadri Nahand J; Asemi Z; Mirzaei H
    Biomed Pharmacother; 2023 Jun; 162():114367. PubMed ID: 37018987
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin.
    Sindelar M; McCabe D; Carroll E
    J Med Toxicol; 2023 Jan; 19(1):45-48. PubMed ID: 36536192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Nonclinical Safety Assessment of Nirmatrelvir Supporting Timely Development of the SARS-COV-2 Antiviral Therapeutic, Paxlovid™.
    Sathish JG; Bhatt S; DaSilva JK; Flynn D; Jenkinson S; Kalgutkar AS; Liu M; Manickam B; Pinkstaff J; Reagan WJ; Shirai N; Shoieb AM; Sirivelu M; Vispute S; Vitsky A; Walters K; Wisialowski TA; Updyke LW
    Int J Toxicol; 2022 Aug; 41(4):276-290. PubMed ID: 35603517
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molnupiravir and Nirmatrelvir-Ritonavir: Oral Coronavirus Disease 2019 Antiviral Drugs.
    Saravolatz LD; Depcinski S; Sharma M
    Clin Infect Dis; 2023 Jan; 76(1):165-171. PubMed ID: 35245942
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
    Marzolini C; Kuritzkes DR; Marra F; Boyle A; Gibbons S; Flexner C; Pozniak A; Boffito M; Waters L; Burger D; Back DJ; Khoo S
    Clin Pharmacol Ther; 2022 Dec; 112(6):1191-1200. PubMed ID: 35567754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimizing the use of Paxlovid in clinical practice.
    McCarthy MW
    Drugs Today (Barc); 2022 Nov; 58(11):539-546. PubMed ID: 36422515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Drug Monitoring and Dosage Adjustments of Immunosuppressive Drugs When Combined With Nirmatrelvir/Ritonavir in Patients With COVID-19.
    Lemaitre F; Budde K; Van Gelder T; Bergan S; Lawson R; Noceti O; Venkataramanan R; Elens L; Moes DJAR; Hesselink DA; Pawinski T; Johnson-Davis KL; De Winter BCM; Pattanaik S; Brunet M; Masuda S; Langman LJ
    Ther Drug Monit; 2023 Apr; 45(2):191-199. PubMed ID: 35944126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Nirmatrelvir/Ritonavir Therapy for COVID-19: The Dawn in the Dark?
    Hung YP; Lee JC; Chiu CW; Lee CC; Tsai PJ; Hsu IL; Ko WC
    Antibiotics (Basel); 2022 Feb; 11(2):. PubMed ID: 35203821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical discovery and development of nirmatrelvir/ritonavir combinational therapy for the treatment of COVID-19 and the lessons learned from SARS-COV-2 variants.
    Pagliano P; Spera A; Sellitto C; Scarpati G; Folliero V; Piazza O; Franci G; Conti V; Ascione T
    Expert Opin Drug Discov; 2023; 18(12):1301-1311. PubMed ID: 37614103
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptative Strategy of Immunosuppressive Drugs Dosage Adjustments When Combined With Nirmatrelvir/Ritonavir in Solid Organ Transplant Recipients With COVID-19.
    Boland L; Devresse A; Monchaud C; Briol S; Belaiche S; Giguet B; Couzi L; Thaunat O; Esposito L; Meszaros M; Roussoulieres A; Haufroid V; Le Meur Y; Lemaitre F
    Transpl Int; 2024; 37():12360. PubMed ID: 38596505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nirmatrelvir and ritonavir combination: an antiviral therapy for COVID-19.
    Navitha Reddy G; Jogvanshi A; Naikwadi S; Sonti R
    Expert Rev Anti Infect Ther; 2023; 21(9):943-955. PubMed ID: 37525997
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Comprehensive Review of the Clinical Pharmacokinetics, Pharmacodynamics, and Drug Interactions of Nirmatrelvir/Ritonavir.
    Gerhart J; Cox DS; Singh RSP; Chan PLS; Rao R; Allen R; Shi H; Masters JC; Damle B
    Clin Pharmacokinet; 2024 Jan; 63(1):27-42. PubMed ID: 38177893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with End-Stage Renal Disease on Intermittent Hemodialysis.
    Lingscheid T; Kinzig M; Krüger A; Müller N; Bölke G; Tober-Lau P; Münn F; Kriedemann H; Witzenrath M; Sander LE; Sörgel F; Kurth F
    Antimicrob Agents Chemother; 2022 Nov; 66(11):e0122922. PubMed ID: 36286542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of nirmatrelvir-ritonavir on viral clearance and length of hospital stay in patients infected with SARS-CoV-2 omicron variants.
    Wang Y; Zhao D; Chen X; Liu X; Xiao W; Feng L
    Influenza Other Respir Viruses; 2023 Feb; 17(2):e13095. PubMed ID: 36843224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Physiologically-Based Pharmacokinetic Modeling of PAXLOVID™ with First-Order Absorption Kinetics.
    Sagawa K; Lin J; Jaini R; Di L
    Pharm Res; 2023 Aug; 40(8):1927-1938. PubMed ID: 37231296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic Surveillance of SARS-CoV-2 M
    Lee JT; Yang Q; Gribenko A; Perrin BS; Zhu Y; Cardin R; Liberator PA; Anderson AS; Hao L
    mBio; 2022 Aug; 13(4):e0086922. PubMed ID: 35862764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dosing recommendation of nirmatrelvir/ritonavir using an integrated population pharmacokinetic analysis.
    Chan PLS; Singh RSP; Cox DS; Shi H; Damle B; Nicholas T
    CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1897-1910. PubMed ID: 37803876
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reproductive and developmental safety of nirmatrelvir (PF-07321332), an oral SARS-CoV-2 M
    Catlin NR; Bowman CJ; Campion SN; Cheung JR; Nowland WS; Sathish JG; Stethem CM; Updyke L; Cappon GD
    Reprod Toxicol; 2022 Mar; 108():56-61. PubMed ID: 35101563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.